Novel oral glucose lowering drugs reduce adverse events in type 2 diabetes

Novel oral glucose lowering drugs are associated with reduced risks of all-cause mortality and CVD.
Novel oral glucose lowering drugs are associated with reduced risks of all-cause mortality and CVD.

(HealthDay News) — For patients with type 2 diabetes, novel oral glucose lowering drugs (GLDs) are associated with reduced risks of all-cause mortality, cardiovascular disease (CVD), and hypoglycemia, compared with insulin use, according to a study published in Diabetes, Obesity and Metabolism.

Thomas Nyström, MD, from Karolinska Institutet in Stockholm, and colleagues compared use of novel oral GLDs (either dipeptidyl-peptidase-4 inhibitors [DPP-4i] or sodium glucose cotransporter-2 inhibitors) with insulin treatment in a propensity score matched analysis involving 21,758 patients matched in a 1:1 ratio.

 

The researchers observed reductions in the risk of all-cause mortality, CVD, and hypoglycemia in the novel GLD group vs the insulin group (hazard ratios [HRs], 0.56, 0.85, and 0.26, respectively). Dapagliflozin correlated with lower risks of all-cause mortality and CVD (HRs, 0.44 and 0.51, respectively), while DPP-4i correlated with reduced risk of all-cause mortality (HR, 0.59) but not CVD (HR, 0.87).

"Dapagliflozin was associated with lower risk of both all-cause mortality and CVD, whereas DPP-4i was only associated with lower risk of all-cause mortality," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Reference

  1. Nystrom T, Bodegard J, Nathanson D, et al. Novel oral glucose-lowering drugs compared to insulin are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycemia in type 2 diabetes patients. Diabetes Obes Metab. 2017. doi:10.1111/dom.12889
You must be a registered member of Clinical Advisor to post a comment.

Sign Up for Free e-newsletters